HCM — HUTCHMED (China) Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1648257 ·
Hong Kong
Last close
$11.13
Market Cap
$1.93B
52W High
$13.55
52W Low
$9.77
ADV30
51,233
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,753,097,000 | 71,330,000 | 501,835,000 |
| Jun 2025 | — | — | — | — | 1,775,940,000 | — | — |
| Dec 2024 | — | — | — | — | 1,274,196,000 | 153,958,000 | 502,343,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-378,643,000
Inventory
$41,129,000
Receivables
—
ST Investments
$1,295,945,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$549,121,984
EBITDA
$-20,515,000
Free Cash Flow
$-18,880,250
Enterprise Value
$666,795,712
Total Cash
$1,376,455,936
Total Debt
$94,508,000
Shares Out
173,814,168
Trailing EPS
$0.10
Book Value
$7.25
ROE
1.5%
ROA
-1.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 548,512,000 | -35,700,000 | 456,909,000 | 1,753,097,000 | 501,835,000 | — | -64,657,000 |
| Dec 2024 | 630,201,000 | -40,610,000 | 37,729,000 | 1,274,196,000 | 502,343,000 | — | 497,000 |
| Dec 2023 | 837,999,000 | 21,509,000 | 100,780,000 | 1,279,773,000 | 536,386,000 | — | 219,258,000 |
| Dec 2022 | 426,409,000 | -406,259,000 | -360,835,000 | 1,029,445,000 | 392,575,000 | — | -268,599,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.23
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $11.13 · call volume: 3 · put volume: 11
Expected Move to 2026-08-21:
±$1.94
(17.43%) —
implied range
$9.19 –
$13.07
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GHRS | GH Research PLC | $1.93B | $28.07 | — |
| NBTX | Nanobiotix S.A. | $1.95B | $38.38 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.91B | $14.88 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.96B | $40.98 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.97B | $10.01 | — |
News headlines (Yahoo Finance, 1h cache)
HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and ...
2026-07-30 19:02 · Yahoo
HUTCHMED H1 Earnings Call Highlights
2026-07-30 17:04 · Yahoo
HUTCHMED Reports 2026 Interim Results
2026-07-30 11:00 · Yahoo
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
2026-07-02 08:30 · Yahoo
HUTCHMED to Announce 2026 Half-Year Financial Results
2026-06-30 08:30 · Yahoo
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
2026-06-25 00:00 · Yahoo
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
2026-06-12 00:00 · Yahoo
Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating
2026-06-02 13:58 · Yahoo
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Ren
2026-05-21 10:00 · Yahoo
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Ren
2026-05-21 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.